New insider activity at Quest Diagnostics ( (DGX) ) has taken place on February 8, 2025.
In a notable series of transactions, Director Vicky Gregg sold 1,250 shares of Quest Diagnostics stock, netting a total of $205,700. In a separate transaction, Senior Vice President and Chief Communications Officer Mark E. Delaney sold 403 shares, amounting to $66,212. These transactions highlight significant activity among Quest Diagnostics’ top executives.
Recent Updates on DGX stock
Quest Diagnostics has seen recent positive developments, leading to several analysts raising their price targets. Mizuho increased the price target based on strong earnings visibility, driven by healthcare utilization and market share gains. Piper Sandler highlighted the company’s growth in higher margin testing areas following their quarterly results. Truist emphasized Quest’s organic revenue growth and expected M&A activity as attractive factors. Baird also raised their price target, maintaining an outperform rating. The company’s Q4 earnings call revealed robust revenue growth from strategic acquisitions, such as LifeLabs, and expansion in Advanced Diagnostics. Despite challenges like weather impacts and pricing pressure in the hospital segment, Quest maintains a positive outlook due to operational efficiencies and consumer testing growth, with optimistic guidance for 2025.
More about Quest Diagnostics
YTD Price Performance: 8.34%
Average Trading Volume: 910,808
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $18.15B